T cell exclusion, immune privilege, and the tumor microenvironment - PubMed (original) (raw)
Review
. 2015 Apr 3;348(6230):74-80.
doi: 10.1126/science.aaa6204.
Affiliations
- PMID: 25838376
- DOI: 10.1126/science.aaa6204
Review
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A Joyce et al. Science. 2015.
Abstract
Effective immunotherapy promotes the killing of cancer cells by cytotoxic T cells. This requires not only that cancer-specific T cells be generated, but also that these T cells physically contact cancer cells. The coexistence in some patients of cancer cells and T cells that recognize them indicates that tumors may exhibit the phenomenon of immune privilege, in which immunogenic tissue is protected from immune attack. Here, we review the evidence that stromal cells of the tumor microenvironment mediate this restriction by excluding T cells from the vicinity of cancer cells. Overcoming this T cell checkpoint may thus enable optimal immunotherapy.
Copyright © 2015, American Association for the Advancement of Science.
Similar articles
- Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D, Yaguchi T, Iwata T, Morii K, Nakagawa T, Nishimura R, Kawakami Y. Kato D, et al. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68. Nihon Rinsho Meneki Gakkai Kaishi. 2017. PMID: 28539557 Review. - Improving the in vivo persistence, distribution and function of cytotoxic T lymphocytes by inhibiting the tumor immunosuppressive microenvironment.
Xu W, Cai J, Li S, Zhang H, Han J, Wen M, Wen J, Gao F. Xu W, et al. Scand J Immunol. 2013 Jul;78(1):50-60. doi: 10.1111/sji.12065. Scand J Immunol. 2013. PMID: 23659474 - Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M, Lee J, Milazzo C, Boczkowski D, Su Z, Nair S, Gilboa E. Fassnacht M, et al. Clin Cancer Res. 2005 Aug 1;11(15):5566-71. doi: 10.1158/1078-0432.CCR-05-0699. Clin Cancer Res. 2005. PMID: 16061874 - Improving homing in T cell therapy.
Vignali D, Kallikourdis M. Vignali D, et al. Cytokine Growth Factor Rev. 2017 Aug;36:107-116. doi: 10.1016/j.cytogfr.2017.06.009. Epub 2017 Jun 23. Cytokine Growth Factor Rev. 2017. PMID: 28690108 Review.
Cited by
- Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases.
de Arruda Camargo GC, Oliveira G, Santos BNS, Roberto IM, Ávila M, de Souza BR, Alonso JCC, Durán N, Fávaro WJ. de Arruda Camargo GC, et al. Med Oncol. 2024 Oct 15;41(11):287. doi: 10.1007/s12032-024-02533-z. Med Oncol. 2024. PMID: 39404781 - Macrophage diversity in cancer dissemination and metastasis.
Mantovani A, Marchesi F, Di Mitri D, Garlanda C. Mantovani A, et al. Cell Mol Immunol. 2024 Oct 14. doi: 10.1038/s41423-024-01216-z. Online ahead of print. Cell Mol Immunol. 2024. PMID: 39402303 Review. - Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune response.
Tan L, Yin T, Xiang H, Wang L, Mudgal P, Chen J, Ding Y, Wang G, Lim BJW, Huang Y, Huang D, Liang Y, Alexander PB, Xiang K, Wang E, Yan C, Ma Z, Tan M, Li QJ, Wang XF. Tan L, et al. Nat Commun. 2024 Oct 3;15(1):8569. doi: 10.1038/s41467-024-52902-5. Nat Commun. 2024. PMID: 39362877 Free PMC article. - PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis.
Blobner J, Dengler L, Eberle C, Herold JJ, Xu T, Beck A, Mühlbauer A, Müller KJ, Teske N, Karschnia P, van den Heuvel D, Schallerer F, Ishikawa-Ankerhold H, Thon N, Tonn JC, Subklewe M, Kobold S, Harter PN, Buchholz VR, von Baumgarten L. Blobner J, et al. Cancer Immunol Immunother. 2024 Oct 3;73(12):255. doi: 10.1007/s00262-024-03837-9. Cancer Immunol Immunother. 2024. PMID: 39358663 Free PMC article. - GPR34 is a metabolic immune checkpoint for ILC1-mediated antitumor immunity.
Yan J, Zhang C, Xu Y, Huang Z, Ye Q, Qian X, Zhu L, Huang G, Wang X, Jiang W, Zhou R. Yan J, et al. Nat Immunol. 2024 Oct 2. doi: 10.1038/s41590-024-01973-z. Online ahead of print. Nat Immunol. 2024. PMID: 39358444
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources